1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Regenxbio Aims For Big Chunk Of Retinal Disease Market With AbbVie-Partnered Gene Therapy

 
• By Alaric DeArment

The company presented promising Phase II data, but it didn’t reveal its plans for a pivotal trial of ABBV-RGX-314, which would compete in a growing – but increasingly crowded – market.

Regenxbio announced interim results from the AAVIATE trial of its gene therapy for wet AMD • Source: Shutterstock

Regenxbio Inc. thinks it could grab a sizable portion of a crowded market for retinal diseases that stands to grow significantly over the next several years with interim Phase II data showing relative stability in best corrected visual acuity (BCVA) and central retinal thickness (CRT) among patients with wet age-related macular degeneration receiving ABBV-RGX-314, the gene therapy it is developing with AbbVie Inc. for retinal diseases. However, Regenxbio is remaining mum about exact plans for its pivotal Phase III trial.

Rockville, MD-based Regenxbio presented results from the Phase II AAVIATE study at the Hawaiian Eye and Retina meeting in Maui on 16 January. The trial compares suprachoroidal delivery of ABBV-RGX-314...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

More from R&D

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

 
• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.